Location:
Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Hotel Phone: (312) 922-4400
Time:
6:30 PM – 7:00 PM — Registration and Dinner Buffet
7:00 PM – 9:30 PM — Educational Meeting
Meeting Room:
Grand Ballroom (Level 2)
There is no registration fee for this event. However, preregistration is advised as seating is limited.
Faculty:
Stephen M Ansell, MD, PhD
Professor of Medicine
Division of Hematology
Mayo Clinic
Rochester, Minnesota
Michelle A Fanale, MD
Associate Professor
Department of Lymphoma and Myeloma
The University of Texas MD Anderson
Cancer Center
Houston, Texas
Christopher Flowers, MD, MS
Associate Professor of Hematology and
Medical Oncology
Emory School of Medicine
Winship Cancer Institute
Atlanta, Georgia
Jonathan W Friedberg, MD, MMSc
Samuel E Durand Professor of Medicine
Director, James P Wilmot Cancer Institute
University of Rochester
Rochester, New York
Noopur Raje, MD
Director, Center for Multiple Myeloma
Massachusetts General Hospital Cancer Center
Professor of Medicine
Harvard Medical School
Boston, Massachusetts
S Vincent Rajkumar, MD
Edward W and Betty Knight Scripps
Professor of Medicine
Division of Hematology
Chair
Myeloma Amyloidosis Dysproteinemia Group
Mayo Clinic
Rochester, Minnesota
Moderator:
Neil Love, MD
Research To Practice
Miami, Florida
Not an official event of the 2017 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO or the Conquer Cancer Foundation.
MODULE 1: Newly Diagnosed and Relapsed/Refractory (R/R) Multiple Myeloma (MM) — Drs Raje and Rajkumar
Newly Diagnosed MM
Key Publications, Presentations and Cases Related to the Following Topics Will Be Reviewed
- Current role of autologous stem cell transplantation in the era of novel agents
- Optimal selection of induction therapy in the transplant and nontransplant settings; choice of proteasome inhibitor and correlation between minimal residual disease status and clinical outcomes
- Clinical trial evidence to guide the selection of post-transplant and nontransplant maintenance and consolidation therapy for patients with normal- and high-risk disease
- Available data and ongoing investigation of novel agents (eg, daratumumab, elotuzumab, ixazomib, panobinostat) as a component of induction therapy
- Use of bone-targeted therapy in patients with and without documented bone involvement, including those with compromised renal function
Relapsed/Refractory MM
Key Publications, Presentations and Cases Related to the Following Topics Will Be Reviewed
- Optimal selection, sequencing and/or combining of carfilzomib and pomalidomide for patients with R/R disease
- Clinical trial data with the use of daratumumab in the R/R setting; ongoing investigation of subcutaneous delivery in patients with R/R disease
- Mechanism of action, available trial data and practical considerations regarding the current clinical role of elotuzumab
- Incorporation of panobinostat into clinical algorithms for R/R disease
- Other novel agents and strategies in development (eg, oprozomib, venetoclax, isatuximab, immune checkpoint inhibitors, chimeric antigen receptor T-cell therapy)
MODULE 2: Chronic Lymphocytic Leukemia (CLL)/Follicular Lymphoma (FL)/Mantle Cell Lymphoma (MCL) — Drs Flowers and Friedberg
Chronic Lymphocytic Leukemia
Key Publications, Presentations and Cases Related to the Following Topics Will Be Reviewed
- Clinical and biologic factors affecting the selection of induction therapy for patients with CLL who require active treatment
- Clinical trial data supporting the use of maintenance therapy in patients with high-risk CLL
- Evidence-based incorporation of obinutuzumab, ibrutinib and idelalisib into the management of CLL
- Mechanism of action, tolerability and ongoing investigation of the second-generation BTK inhibitor acalabrutinib
- Integration of venetoclax into the treatment algorithm for patients with R/R del(17p) CLL and recommendations for tumor lysis syndrome prevention
Follicular Lymphoma
Key Publications, Presentations and Cases Related to the Following Topics Will Be Reviewed
- Role of obinutuzumab with chemotherapy as up-front therapy for patients with treatment-naïve FL
- Comparative safety and efficacy of subcutaneous versus intravenous administration of rituximab in FL and other lymphomas
- Available research data and ongoing evaluation of rituximab/lenalidomide (R2) in the management of R/R FL and as induction therapy
- Appropriate integration of idelalisib into current treatment algorithms; recognition, prevention and management of idelalisib-related toxicities
- Efficacy and ongoing investigation of novel agents in FL (eg, copanlisib, ibrutinib, venetoclax)
Mantle Cell Lymphoma
Key Publications, Presentations and Cases Related to the Following Topics Will Be Reviewed
- Evidence-based selection of induction and maintenance therapy for younger and older patients with newly diagnosed MCL
- Available and emerging research information evaluating the use of novel agents as a component of induction and/or post-transplant maintenance therapy
- Available data with and optimal sequencing of ibrutinib, bortezomib and lenalidomide for R/R disease
- Mechanistic diversity among and available data with novel agents in development for MCL
MODULE 3: Hodgkin Lymphoma (HL)/Diffuse Large B-Cell Lymphoma (DLBCL)/T-Cell Lymphoma (TCL) — Drs Ansell and Fanale
Hodgkin Lymphoma
Key Publications, Presentations and Cases Related to the Following Topics Will Be Reviewed
- Preliminary outcomes and ongoing evaluation of brentuximab vedotin (BV) as a component of first-line therapy; current management approaches for elderly patients
- Indications for and practical considerations with the use of BV as a bridge to or as consolidation after transplant
- FDA approvals of nivolumab and pembrolizumab for patients with R/R HL; patient selection for anti-PD-1 therapy and practical considerations regarding administration
- Ongoing evaluation of immune checkpoint inhibitors alone or in combination with other immunotherapies or targeted agents in HL
Diffuse Large B-Cell Lymphoma
Key Publications, Presentations and Cases Related to the Following Topics Will Be Reviewed
- Available and emerging research information with lenalidomide and ibrutinib in newly diagnosed and R/R DLBCL
- Indications for CD30 testing and current role, if any, of BV in the management of CD30-positive and negative DLBCL
- Biologic rationale for, available data with and ongoing trials of chimeric antigen receptor T-cell therapy
- Other novel strategies under investigation in R/R DLBCL
T-Cell Lymphoma
Key Publications, Presentations and Cases Related to the Following Topics Will Be Reviewed
- Current role of CD30 analysis for patients with TCL; potential role of BV in CD30-positive disease
- Patient- and/or disease-specific factors guiding the sequence and selection of belinostat, pralatrexate and romidepsin in TCL
- Emerging research information with immune checkpoint inhibitors and other promising strategies for patients with specific TCL subtypes
Target Audience:
This program is intended for medical oncologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of hematologic cancers.
Learning Objectives and Goals:
At the conclusion of this activity, participants should be able to:
- Customize the use of induction, consolidation and maintenance therapeutic approaches for patients with multiple myeloma (MM) in the post-transplant and nontransplant settings, considering patient- and disease-related factors, including cytogenetic profile.
- Consider available research data and other clinical factors in the best-practice selection, sequencing or combining of carfilzomib and pomalidomide in the nonresearch care of patients with relapsed/refractory (R/R) MM.
- Recognize the recent FDA approvals of daratumumab, elotuzumab, ixazomib and panobinostat, and effectively identify where and how these novel agents should be integrated into the clinical management of R/R MM.
- Individualize the selection and sequence of systemic therapy for patients with newly diagnosed and R/R chronic lymphocytic leukemia (CLL), considering the patient’s clinical presentation, biomarker profile and psychosocial status.
- Consider existing and emerging clinical research data in the formulation of therapeutic recommendations for patients with newly diagnosed and R/R diffuse large B-cell lymphoma, follicular lymphoma and mantle cell lymphoma.
- Assess the benefits and risks of evidence-based systemic treatment options to individualize and optimize the care of patients with T-cell lymphoma.
- Review emerging clinical trial data on the efficacy and safety of brentuximab vedotin for patients with Hodgkin lymphoma (HL) and other CD30-positive lymphomas, and use this information to prioritize protocol and nonresearch options for these patients.
- Compare and contrast the mechanisms of action, efficacy and safety of approved and investigational immunotherapeutic approaches (eg, checkpoint inhibitors, chimeric antigen receptor-directed T-cell therapy) for the treatment of HL and non-Hodgkin lymphoma to determine the current and/or potential utility of each in clinical practice.
- Assess the ongoing clinical trials evaluating other novel investigational approaches for HL, NHL, CLL and MM, and obtain consent from appropriate patients for study participation.
CME Credit Form:
A CME credit form will be given to each participant at the conclusion of the activity.
Accreditation Statement:
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation Statement:
Research To Practice designates this live activity for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure Policy:
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.
Supporters:
This activity is supported by educational grants from AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP/Acerta Pharma, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology, Kite Pharma Inc and Seattle Genetics.
Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Hotel Phone: (312) 922-4400
Meeting Room:
Grand Ballroom (Level 2)
Directions:
The Hilton Chicago hotel is located just 5 minutes (2.5 miles) north of the McCormick Place convention center, where the ASCO Annual Meeting is taking place.
Thank you for your interest in our educational program. At this time online preregistration is closed. However, seats are still available for the conference. Onsite registration will be open starting at 6:30 PM (Central Time) on Sunday, June 4th. If you are interested in attending, please visit our registration desk in the Grand Ballroom foyer located on the second level of the Hilton Chicago hotel (720 Michigan Avenue, Chicago, IL).
Please note, onsite registrant seating will be prioritized for healthcare professionals directly involved in the care of patients. If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com or call (800) 233-6153.
|
